<DOC>
	<DOCNO>NCT02297204</DOCNO>
	<brief_summary>The Endurance Trial phase IV open label clinical study ass need ongoing intravitreal aflibercept injection 3-year VISTA DME ( VGFT-OD-1009 ) end-point . Subjects treat intravitreal aflibercept injection pro nata ( PRN ) base presence CR-DME ( Clinically Relevant-Diabetic Macular Edema ) . In addition , subject meet re-treatment criterion eligible focal laser treatment every 90 day .</brief_summary>
	<brief_title>The Endurance 1 Trial</brief_title>
	<detailed_description>The safety tolerability intravitreal aflibercept injection investigate previous Phase I , I/II III study AMD , RVO , DME trial . Potential safety issue associate route administration pharmacology aflibercept study population include decrease BCVA , intraocular inflammation , intraocular infection , transient and/or sustain elevation intraocular pressure ( IOP ) , cataract development progression , retinal intravitreal hemorrhage , macular edema , retinal break detachment , arterial thromboembolic event ( ATEs ) . Safety assess visual acuity , ophthalmic examination , fluorescein angiogram , OCT , intraocular pressure , vital sign , adverse event documentation . To minimize risk intraocular infection , injection perform employ sterile technique describe Appendix A . Study drug administration hold subject experience certain ocular event infection . In event subject develop adverse event study eye consider evaluate physician severe intensity , serious consideration give withdraw subject study . The PI designate Sub-Investigators review adverse event ongoing basis determine causality relationship study drug and/or study procedure .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<criteria>1 . Enrolled Completed VISTA DME ( VGFTOD1009 ) clinical trial 2 . Willing able comply clinic visit studyrelated procedure 3 . Provide sign informed consent 4 . Enrollment trial within 12 week trial activation . 1 . Prior treatment antiVEGF therapy study eye within 28 day baseline 2 . Pregnant breastfeed woman 3 . Sexually active men* woman childbearing potential** unwilling practice adequate contraception study ( adequate contraceptive measure include stable use oral contraceptive prescription pharmaceutical contraceptive 2 menstrual cycle prior screen ; intrauterine device [ IUD ] ; bilateral tubal ligation ; vasectomy ; condom plus contraceptive sponge , foam , jelly , diaphragm plus contraceptive sponge , foam , jelly ) . Contraception require men document vasectomy . **Postmenopausal woman must amenorrheic least 12 month order consider child bear potential . Pregnancy test contraception require woman document hysterectomy tubal ligation .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>